<DOC>
	<DOCNO>NCT00003007</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Peripheral stem cell transplantation may allow doctor give high dos chemotherapy drug kill tumor cell . Interferon alfa may interfere growth cancer cell . PURPOSE : Phase II trial determine effectiveness give interferon alfa chemotherapy peripheral stem cell transplantation patient stage III stage IV multiple myeloma treat high-dose melphalan .</brief_summary>
	<brief_title>Interferon Alfa Following Chemotherapy Peripheral Stem Cell Transplantation Treating Patients With Stage III Stage IV Multiple Myeloma</brief_title>
	<detailed_description>OBJECTIVES : I . Determine effectiveness interferon alfa-2b maintenance follow high dose melphalan chemotherapy patient advance multiple myeloma . II . Determine response rate high dose dexamethasone therapy use sequential noncrossresistant chemotherapy patient advance multiple myeloma . OUTLINE : Patients receive high dose dexamethasone day 1-4 , 9-12 , 17-20 , follow 4 week rest . Cyclophosphamide ( CTX ) administer intravenously combination mesna follow dexamethasone therapy . Sargramostim ( GM-CSF ) initiate subcutaneously 1 day later continue 10 day support stem cell collection , begin 10-14 day CTX induction . Following 4 week rest , melphalan ( L-PAM ) administer 1 hour . Stem cell rescue begin 48 hour L-PAM therapy . Three 4 month first L-PAM course , second L-PAM stem cell rescue undertaken . Interferon alfa-2b ( IFN-A ) maintenance administer 3 time per week follow bone marrow recovery first second L-PAM course . Patients achieve complete remission follow first course L-PAM may proceed directly IFN-A maintenance . Patients achieve great grade 3 nonhematologic toxicity achieve absolute neutrophil count great 1,000/mm3 day 21 posttransplant eligible dose escalation . PROJECTED ACCRUAL : A minimum 30 patient enrol .</detailed_description>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Plasmacytoma</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Melphalan</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : See General Eligibility Criteria PATIENT CHARACTERISTICS : Age : 19 64 Performance Status : Zubrod 03 Hematopoietic : Not specify Hepatic : Bilirubin le 2 mg/dL SGOT SGPT less 3 time normal Alkaline phosphatase less 3 time normal Renal : Creatinine clearance least 60 mL/min Cardiovascular : Cardiac ejection fraction least 50 % Pulmonary : No history severe chronic obstructive lung disease No history recurrent pulmonary embolus Other : Not pregnant nursing Effective contraception practice fertile patient No history diabetes mellitus complicate ketoacidosis No history depression psychosis No history autoimmune disorder No concurrent thyroid disorder unable maintain replacement therapy No prior hypersensitivity interferon alfa2b PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : No 12 month prior alkylator therapy Endocrine Therapy : Not specify Radiotherapy : Not specify Surgery : Not specify</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>64 Years</maximum_age>
	<verification_date>September 2002</verification_date>
	<keyword>refractory multiple myeloma</keyword>
	<keyword>stage III multiple myeloma</keyword>
</DOC>